See more : Daiseki Co.,Ltd. (9793.T) Income Statement Analysis – Financial Results
Complete financial analysis of PepGen Inc. (PEPG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PepGen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lake Victoria Gold Ltd. (LVG.V) Income Statement Analysis – Financial Results
- Victory Oilfield Tech, Inc. (VYEY) Income Statement Analysis – Financial Results
- Consilium Acquisition Corp I, Ltd. (CSLM) Income Statement Analysis – Financial Results
- DKSH Holding AG (0QQE.L) Income Statement Analysis – Financial Results
- Rex Sealing and Packing Indust (REXSEAL.BO) Income Statement Analysis – Financial Results
PepGen Inc. (PEPG)
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| Gross Profit | -1.18M | -493.00K | -178.00K | -110.00K | -106.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.94M | 54.08M | 19.00M | 1.02M | 620.00K |
| General & Administrative | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 627.37K |
| SG&A | 16.64M | 14.22M | 8.11M | 853.00K | 628.00K |
| Other Expenses | 0.00 | 110.00K | -172.00K | -20.00K | 0.00 |
| Operating Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.25M |
| Cost & Expenses | 84.77M | 68.30M | 27.11M | 1.88M | 1.35M |
| Interest Income | 6.40M | 2.79M | 0.00 | 8.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.18M | 493.00K | 178.00K | 110.00K | 106.00K |
| EBITDA | -83.58M | -67.81M | -26.93M | -1.77M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -84.77M | -68.30M | -27.11M | -1.88M | -1.35M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 2.90M | -172.00K | -12.00K | 8.00K |
| Income Before Tax | -78.55M | -65.40M | -27.28M | -1.89M | -1.35M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 73.00K | 3.71M | -58.56K | -8.00K | 0.00 |
| Net Income | -78.63M | -69.10M | -27.28M | -1.88M | -1.35M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| EPS Diluted | -3.30 | -2.91 | -1.22 | -0.08 | -0.06 |
| Weighted Avg Shares Out | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
| Weighted Avg Shares Out (Dil) | 23.80M | 23.71M | 22.39M | 22.39M | 22.39M |
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement...
PepGen to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor...
PepGen Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into PepGen Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Inc. Is Being Investigated For Securities Related Infractions And The Schall Law Firm Encourages Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Investors Are Invited To Join The Schall Law Firm's Inquiry Into PepGen Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Encourages Affected Shareholders To Take Part
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into PepGen Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
PepGen Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Encourages Affected Shareholders To Lend A Hand
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Investors Are Invited To Take Part In The Schall Law Firm's Inquiry Into PepGen Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations...
Source: https://incomestatements.info
Category: Stock Reports